Skip to main content
OpenTrials
Completed

NCT Number: NCT02211157

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Study to assess safety, pharmacokinetics and pharmacodynamics of BIRB 796 BS in escalating multiple doses with and without a 64 g fat breakfast at the 50 mg dose level

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects as determined by results of screening
  • Signed written informed consent in accordance with Good Clinical Practice and local legislation
  • Age ≥ 18 and ≤ 45 years
  • Broca ≥ - 20% and ≤ + 20%

Exclusion criteria

  • Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • History of orthostatic hypotension, fainting spells and blackouts
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (>24 hours) within 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the results of the trial within 10 days prior to administration or during trial
  • Participation in another trial with an investigational drug within 2 months prior to administration or during trial
  • Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation > 400 ml within 1 month prior to administration or during the trial
  • Excessive physical activities within 5 days prior to administration or during the trial
  • Any laboratory value outside the reference range of clinical relevance including, but not limited to total white cell count ≥ 10 x 10**9/L, C-reactive protein ≥ 4.5 mg/L, Gamma-Glutamyl Transferase ≥ 40 U/L, any hemoglobin or > 15 mg/dl protein or urine dipstick, abnormal Multitest® assessment of cellular immunity
  • History of any familial bleeding disorder
  • Inability to comply with dietary regimen of study centre

Treatment and study plan

BIBR 796 BS

Drug

Placebo

Drug

High fat breakfast

Other

Primary outcomes

  1. Number of patients with clinically relevant changes in laboratory parameters

    Time frame: up to day 16

  2. Number of patients with abnormal findings in electrocardiogram (ECG)

    Time frame: up to day 16

  3. Number of patients with adverse events

    Time frame: up to 30 days

  4. Assessment of tolerability on a 4-point scale

    Time frame: day 16

  5. Number of patients with clinically relevant changes in vital signs

    Time frame: up to 16 days

Secondary outcomes

  1. Maximum plasma concentration (Cmax) for several time points

    Time frame: up to day 9

  2. Area under the plasma concentration-time curve (AUC) for several time points

    Time frame: up to day 9

  3. Time to maximum concentration (tmax)

    Time frame: up to day 9

  4. Elimination rate constant (λz)

    Time frame: up to day 9

  5. Terminal half-life (t1/2)

    Time frame: up to day 9

  6. Mean residence time (MRT)

    Time frame: up to day 9

  7. Apparent clearance (CL/f)

    Time frame: up to day 9

  8. Apparent volume of distribution (Vz/F)

    Time frame: up to day 9

  9. Assessment of neutrophil and monocyte activation by ex vivo stimulation of whole blood with formyl-methionyl-leucyl-phenylalanine (fMLP)

    Time frame: up to day 9

    Change in the Mac-1 / L-selectin ratio

  10. Assessment of neutrophil and monocyte activation by ex vivo stimulation of whole blood with tumour necrosis factor (TNF) α

    Time frame: up to day 9

    Change in the Mac-1 / L-selectin ratio

  11. Assessment of TNFα production by ex vivo stimulation of whole blood with endotoxin

    Time frame: up to day 9

  12. Changes in cellular immune response measured by Multitest®

    Time frame: Day 8

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets (20, 30, 150, 300, and 600 mg) Administered Orally to Healthy Human Subjects Once Daily for 7 Days. A Placebo Controlled, Randomised, Double Blinded Study

Important dates

Study start
2000
Primary completion
2000
First posted
Aug 7, 2014
Registry last updated
Aug 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.